Avalyn Pharma Inc. Common Stock (AVLN) Stock Grade

About Avalyn Pharma Inc. Common Stock's fundamentals

Avalyn Pharma is a biotech company with a market capitalization of $1.3 billion that reported zero year-over-year revenue growth and a net loss in its latest annual statement, resulting in a 0.0% net margin. The company generated a 35.7% return on equity despite the loss, which reflects how it deployed shareholder capital during the period. With no dividend yield and no meaningful earnings to calculate a P/E ratio, the company's financial profile is typical of early-stage biotechnology firms that prioritize research and development spending over profitability.